Ventyx Biosciences, Inc. (VTYX) – Financial Analysis and Stock Price Prediction
Company Overview
- Company Name: Ventyx Biosciences, Inc.
- Ticker Symbol: VTYX
- Industry: Biotechnology
- Sector: Healthcare
- Website: https://ventyxbio.com
- Address: 12790 El Camino Real, Suite 200, San Diego, CA 92130, United States
- Phone: 760 593 4832
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates to address inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. Ventyx Biosciences is also developing other product candidates such as VTX002 for ulcerative colitis, VTX2735 for cryopyrin-associated periodic syndrome, and VTX3232 for CNS disorders.
Financial Analysis
- Market Cap: $412.7 million
- Fiscal Year: 2022
- Full-time Employees: 79
- Revenue: Not available
- Net Income: -$192.96 million
- Profit Margins: Not available
- Trailing EPS: -$3.3
- Forward EPS: -$2.59
- P/E Ratio: Not available
- Payout Ratio: 0%
- Dividend Yield: 0%
- Debt to Equity Ratio: 5.127
Ventyx Biosciences, Inc. has a negative net income and trailing EPS, indicating that the company is currently not profitable. The company's debt to equity ratio is relatively high, suggesting a higher level of debt compared to equity.
Stock Price Analysis
- Previous Close: $6.54
- Open: $6.51
- Day Range: $5.83 – $6.6
- 52-Week Range: $1.87 – $40.58
- Volume: 1,573,802 shares
- Average Volume: 4,478,200 shares
- Market Price: $5.86
- Target Price: $10.8 (Mean)
- Recommendation: Buy (Mean)
The stock price of Ventyx Biosciences, Inc. has a 52-week range of $1.87 to $40.58, indicating significant volatility in the past year. The current market price is $5.86. Analysts have a mean target price of $10.8 and recommend buying the stock.
Prediction
Based on the financial analysis and stock price indicators, it is important to note that Ventyx Biosciences, Inc. is a high-risk investment due to its negative net income, high debt to equity ratio, and significant stock price volatility. However, analysts recommend buying the stock, suggesting potential future growth. Investors should carefully assess the company's financial position and market conditions before making any investment decisions.
